1. Home
  2. SWTX vs CNK Comparison

SWTX vs CNK Comparison

Compare SWTX & CNK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SWTX
  • CNK
  • Stock Information
  • Founded
  • SWTX 2017
  • CNK 1984
  • Country
  • SWTX United States
  • CNK United States
  • Employees
  • SWTX N/A
  • CNK N/A
  • Industry
  • SWTX Biotechnology: Pharmaceutical Preparations
  • CNK Movies/Entertainment
  • Sector
  • SWTX Health Care
  • CNK Consumer Discretionary
  • Exchange
  • SWTX Nasdaq
  • CNK Nasdaq
  • Market Cap
  • SWTX 3.5B
  • CNK 3.2B
  • IPO Year
  • SWTX 2019
  • CNK 2007
  • Fundamental
  • Price
  • SWTX $46.26
  • CNK $31.23
  • Analyst Decision
  • SWTX Buy
  • CNK Buy
  • Analyst Count
  • SWTX 7
  • CNK 12
  • Target Price
  • SWTX $56.86
  • CNK $33.00
  • AVG Volume (30 Days)
  • SWTX 8.7M
  • CNK 3.7M
  • Earning Date
  • SWTX 05-20-2025
  • CNK 05-02-2025
  • Dividend Yield
  • SWTX N/A
  • CNK 0.26%
  • EPS Growth
  • SWTX N/A
  • CNK 16.58
  • EPS
  • SWTX N/A
  • CNK 1.71
  • Revenue
  • SWTX $191,589,000.00
  • CNK $3,011,000,000.00
  • Revenue This Year
  • SWTX $86.36
  • CNK $8.71
  • Revenue Next Year
  • SWTX $69.02
  • CNK $7.42
  • P/E Ratio
  • SWTX N/A
  • CNK $18.26
  • Revenue Growth
  • SWTX 3417.33
  • CNK N/A
  • 52 Week Low
  • SWTX $28.21
  • CNK $16.32
  • 52 Week High
  • SWTX $62.00
  • CNK $36.28
  • Technical
  • Relative Strength Index (RSI)
  • SWTX 58.93
  • CNK 71.88
  • Support Level
  • SWTX $46.10
  • CNK $27.86
  • Resistance Level
  • SWTX $46.27
  • CNK $31.57
  • Average True Range (ATR)
  • SWTX 0.90
  • CNK 0.99
  • MACD
  • SWTX 0.58
  • CNK 0.11
  • Stochastic Oscillator
  • SWTX 99.46
  • CNK 90.84

About SWTX SpringWorks Therapeutics Inc.

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.

About CNK Cinemark Holdings Inc Cinemark Holdings Inc.

Cinemark Holdings Inc is a geographically diverse operator in the motion picture exhibition industry in the United States. The company generates revenue from filmed entertainment box office receipts and concession sales, with additional revenue from screen advertising, screen rentals, and other revenue streams, such as transactional fees, vendor marketing promotions, studio trailer placements, meeting rentals, and electronic video games located in some of the theatres.

Share on Social Networks: